IceCure Medical (ICCM) said Thursday it expects a US Food and Drug Administration decision regarding its De Novo marketing authorization request for ProSense as a potential treatment for early-stage low-risk breast cancer with endocrine therapy after Q1.
The company said it remains in continued discussions with the FDA regarding the request.
"Given the novelty of our product and the importance of breast cancer in public health, the FDA has included many stakeholders in the discussion," said IceCure Chief Executive Eyal Shamir.
Shares of the company were down more than 17% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。